Month: August 2021

SANTA MONICA, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the closing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of $8.00 per share, for gross proceeds of $20,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to cover over-allotments at the offering price, less the underwriting discount. ThinkEquity, a division of Fordham Financial Management, Inc., acted as the sole...

On June 23rd Skeljungur published a notice to the effect that the Board of Directors of the Company had made a decision to assess the advantages of the Company’s future ownership of its real properties, and that the Company would be advised on the matter by Íslandsbanki’s corporate advisory team. Since that time, work has been in progress on valuating the company’s real estate assets in the metropolitan area of the capital, and also in Westland and Reykjanes. The Board of Directors of the Company has now made a decision to place following assets in a process of divestment with a view to leasing the properties back (sales and lease back), either in full or in part. These are the following selected assets (note the below list is not exhaustive): – Austurströnd 7 (Suðurströnd), 170 Seltjarnarnes– Birkimelur 1, 107 Reykjavík–...

The agreement is for five years, valued at USD 240 million, with an option to extend for an additional five years ART will provide its Resid Hydrocracking catalyst and full-cycle catalyst management (FCM) solutions This award is part of the Bapco Modernization Programme (BMP) to boost processing capacity at the refineryCOLUMBIA, Md., Aug. 11, 2021 (GLOBE NEWSWIRE) — Advanced Refining Technologies LLC (ART), the joint venture of US specialty chemicals and materials company W. R. Grace & Co. (NYSE:GRA) and US energy company Chevron (NYSE:CVX), today announced the award of an FCM agreement by state-owned Bahrain Petroleum Company (Bapco). The exclusive, 5-year agreement, which includes an option to renew for an additional five years, is valued at USD 240 million, the largest catalyst management agreement ever signed in Bapco’s...

Volta Finance Limited (VTA / VTAS) – July 2021 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 11 August 2021 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for July. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY Volta had a good performance in July, gaining +2.5% including a €0.14 dividend. That brings the total return of the fund to 14.1% year-to-date. The monthly asset class performances** were: +1.7% for Bank Balance Sheet transactions, +5.0% for CLO equity tranches; +0.6% for CLO debt; -1.4% for Cash Corporate Credit and ABS (together representing 3.2% of GAV). As expected, July 2021 was a new...

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ CALGARY, Alberta, Aug. 11, 2021 (GLOBE NEWSWIRE) — Bayshore Petroleum Corp. is pleased to announce it has successfully held its annual general and special meeting (AGSM) on August 6, 2021. The AGSM has approved the following resolutions.(1) Consolidation of Share Capital on the basis of one (1) post-consolidation common shares for each thirty-nine point four five six nine (39.4569) PRE-CONSOLIDATION COMMON SHARES.(2) Change of name from Bayshore Petroleum Corp. to Infinitum Copper Corp.(3) Continuation of the Corporation into the province of British Columbia(4) To fix the number of board members for the Corporation and number of board members conditionally after the closing of the Acquisition(5) Election of current directors...

ROSELAND, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it will host a conference call at 11:00 A.M. Eastern Time on Monday, August 16, 2021 to discuss the Company’s financial results for the second quarter ended June 30, 2021, as well as the Company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 1- 844-369-8770 for U.S. callers or 862-298-0840 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2306/42492 or on the Company’s website at https://www.milestonescientific.com/. An audio replay of the call will be available through August...

RELEASE Paris, August 11, 2021 INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPRISING THE SHARE CAPITALIn accordance with the provisions of Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF), Hermès international publishes each month, before the 15th day of the following month, the total number of voting rights and the number of shares comprising the share capital if they have varied from those previously published.Date Total number of shares Total number of theoretical voting rights (including treasury stock) Total number of effective voting rights (exercisable at shareholders’ meetings) Publications31 July 2021 105 569 412 178 454 611 177 529 216 11 August 202130 June...

Saint-Herblain (France), August 11th, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced the initiation of a further Phase 3 trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001-304 aims to generate data in the elderly and is also designed to potentially enable variant-bridging through immune-comparability. Data from this study are expected to complement ongoing clinical trials and support additional regulatory submissions. VLA2001-304, which will be conducted in New Zealand, will recruit approximately 150 participants aged 56 years and older (Cohort 1) with the aim of generating additional safety and immunogenicity...